verteporfin

(redirected from Benzoporphyrin derivative)

verteporfin

 [ver″tĕ-por´fin]
a photosensitizing agent that accumulates preferentially in neovasculature, including that in the choroid, such as occurs in age-related macular degeneration, ocular histoplasmosis, or pathologic myopia; the agent is then activated by light of a specific wavelength in the presence of oxygen, and causes local damage to the neovascular endothelium followed by vessel occlusion; it is administered intravenously prior to irradiation of the lesion with light from a compatible laser.

ver·te·por·fin

(vĕr-tē-pōr'fin),
Photosensitizer agent used in photodynamic therapy to treat choroidal neovascularization secondary to age related macular degeneration.

verteporfin

/ver·te·por·fin/ (ver″tĕ-por´fin) a photosensitizing agent that accumulates preferentially in neovasculature, including that in the choroid; used, together with appropriate laser irradiation of the lesion, in the treatment of neovascularization due to disciform macular degeneration, to presumed ocular histoplasmosis, or to pathologic myopia.

verteporfin

[ver′tĕ-por′fin]
a photosensitizing agent that accumulates preferentially in neovasculature, including that in the choroid, such as occurs in age-related macular degeneration, ocular histoplasmosis, or pathological myopia. The agent is then activated by light of a specific wavelength in the presence of oxygen and causes local damage to the neovascular endothelium followed by vessel occlusion. It is administered intravenously before irradiation of the lesion with light from a compatible laser.
References in periodicals archive ?
Four photosensitizing drugs, Photofring, Texas Red, a benzoporphyrin derivative monoacid (BPD), and lutetium texaphyrin (LuTex) were tested to see if they were substrates of the MDR-1 multidrug resistor pump, or if they could be used in PDT.
Quadra Logic is today testing an even stronger free radical-releasing drug called benzoporphyrin derivative, or BPD, which is also activated by light.
QLT's second-generation product, Benzoporphyrin derivative (BPD-MA) is undergoing clinical trials for the treatment of age-related macular degeneration, the leading cause of blindness in the elderly.
In a multi-center Phase I/II clinical trial, co-sponsored by QLT and CIBA Vision, researchers presented preliminary ocular safety and proof-of-principle data suggesting that the light-activated drug, Benzoporphyrin derivative (BPD), can selectively close abnormal blood vessels in the eye that are associated with the severe or "wet" form of Age-related Macular Degeneration (AMD) without causing vision loss associated with currently available treatments.
The Company has several drugs under development, including clinical trials for Benzoporphyrin derivative (BPD), a second-generation photosensitizer.
The Company has several drugs under development, including the approved product PHOTOFRIN(R) and clinical trials for Benzoporphyrin derivative, a second-generation photosensitizer.
The company has several drugs under development, including Benzoporphyrin derivative, a second-generation photosensitizer, currently in clinical trials.
BOSTON, MA--(BUSINESS WIRE)--MAY 2, 1995--QUADRA LOGIC(TSE: QLT NASDAQ: QLTIF) Researchers at the Massachusetts Eye and Ear Infirmary and Harvard Medical School have commenced a Phase I safety and proof- of-concept clinical study involving the use of the light-activated drug, Benzoporphyrin derivative (BPD), as a potential treatment for Age-related Macular Degeneration.
BOSTON--(BUSINESS WIRE)--May 2, 1995--Researchers at the Massachusetts Eye and Ear Infirmary and Harvard Medical School have commenced a Phase I safety and proof- of-concept clinical study involving the use of the light-activated drug, Benzoporphyrin derivative (BPD), as a potential treatment for Age-related Macular Degeneration.
No longer proposed is the granting by QLT to Ciba of an exclusive option to negotiate future rights for cancer and psoriasis applications of QLT's PDT drug, Benzoporphyrin derivative (BPD).
Pending clearance of these submissions, human clinical trials will commence in the United States and Germany, using Benzoporphyrin derivative (BPD) to treat AMD.
11, 1994-- Clinicians in a QLT-sponsored trial have begun using topical formulations of Benzoporphyrin derivative (BPD) activated by Light Emitting Diodes (LEDs) as a potential treatment for moderate- to-severe forms of psoriasis.